PharmaTutor (August- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 8)
Received On: 14/06/2014; Accepted On: 23/06/2014; Published On: 01/08/2014
AUTHORS: Shambhavi Singh
Department of Pharmacology, Singhania University,
Jhunjhunu, Rajasthan
shambhavisingh6777@gmail.com
ABSTRACT:
Cervical cancer, malignant neoplasm, appears in tissues of the cervix, a likely preventable disease that originates as the second most widespread malignancy in women. In spite of being considering as a treatable disease, 95% preventive and conditions that can be easily examined through Pap smear. This disease accounts for a miserable condition, probable 24 percent of India’s cancer cases among women and in addition to that 80,000 Indian women die annually from the disease, which results from the unusual growth of cells in the cervix. No proper vaccination program from Indian government and miserable earning can be said responsible for this condition. Though the disease is both preventable and curable but still mortality rate in India is aggravating subsequently.
How to cite this article: S Singh; Cervical Cancer and its Various Emerging Impact; PharmaTutor; 2014; 2(8); 54-65
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Finding low-cost vaccine could save thousands of poor women: courier-journal 2013 February 15
2. Shambhavi Singh et al. Cervical cancer a curse for growing age women. Pharmatutor.July 2013 edition: Pharmatutor-Art-1895
3. Cervical Cancer (cont.) page: medicinenet.com 2014 may: 13.
4. International Collaboration of Epidemiological Studies of Cervical Cancer. (2007). Lancet 370, 1609-1621.
5. Wingo P. A. et al. Obstetrics & Gynecology 2007.110,793-800.
6. Patrik K. E. Magnusson, Pär Sparén & Ulf B. Gyllensten. Genetic link to cervical tumours: 23 January 2010; 171(4):1283-6.
7. Debbie Barragan et al. Is cervical cancer hereditary?genetics.thetech.org
8. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute. Oxford University Press. 2011, October 5. 103(19):1444-51
9. Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Review of Vaccines. Expert Reviews Ltd. 2013, March. 12(3):271-83.
10.Moyer VA; On behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. American College of Physicians. 2012, June 19. 156(12):880-91
11. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncology. Elsevier. 2012, January. 13(1):78-88
12. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer Journal for Clinicians. American Cancer Society. 2012, March 14.
13.Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. European Journal of Cancer. Elsevier. . 2011, April. 47(6):864-71
14. Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. British Journal of Cancer (BJC). Nature Publishing Group. 2012, December 4. 107(12):1917-24
15.. Cerigo H, Coutlee F, Franco EL, et al. Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. Journal of Medical Screening. RSM Press. 2012, 19(1):42-8
16. Kitchener HC, Blanks R, Dunn G, et al. Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. Lancet Oncology. Elsevier. (2011, Lancet). 12(1):56-64
17.Lecuru F, Mathevet P, Querleu D, et al. Bilateral Negative Sentinel Nodes Accurately Predict Absence of Lymph Node Metastasis in Early Cervical Cancer: Results of the SENTICOL Study. Journal of Clinical Oncology. American Society of Clinical Oncology. 2011, March 28.
18. Cibula D, Abu-Rustum NR, Dusek L, et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecologic Oncology. Academic Press. 2012, March. 124(3):496-501
19.Watari H, Kinoshita R, Han Y, et al. Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy. International Journal of Gynecological Cancer. Lippincott, Wilkins, William. 2012, March. 22(3):465-70).
20.Fotopoulou C. ,Braicu E. I.,Chekerov R., et al. Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy. (2011). ASCO: American Society of Clinical Oncology 2011
21.Nam JH, Park JY, Kim DY, et al. Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. Annals of Oncology. Oxford Journals. 2012, April. 23(4):903-11
22. Sert MB, Abeler V.. Robot-assisted laparoscopic radical hysterectomy: Comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital. Gynecologic 23.Oncology. Academic Press. 2011, February 24).
23. Soliman PT, Frumovitz M, Sun CC, et al. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology.Gynecologic Oncology.Academic Press. 2011, November.123(2):333-6
24. Jackson AL, Kilgore J, Ko EM, et al. Long-term survival following robot-assisted surgical treatment of early cervical cancer. (2013). American Society of Clinical Oncology 2013
25.Sert MB, Abeler V.. Robot-assisted laparoscopic radical hysterectomy: Comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital. Gynecologic 26.Oncology. Academic Press. (2011, February 24).
26. Van de Lande J, von Mensdorff-Pouilly S, Lettinga RG, et al. Open versus laparoscopic pelvic lymph node dissection in early stage cervical cancer: no difference in surgical or disease outcome. International Journal of Gynecological Cancer. Lippincott, Wilkins, William. 2012, January. 22(1):107-14
27.Plotti F, Nelaj E, Sansone M,. Sexual function after modified radical hysterectomy (Piver II/Type B) vs. classic radical hysterectomy (Piver III/Type C2) for early stage cervical cancer. A prospective study. International Journal of Impotence Research: The Journal of Sexual Medicine. Nature Publishing Group. 2012, March. 9(3):909-17.
28.Manjunath AP, Girija S. Embryologically based resection of cervical cancers: a new concept of surgical radicality.Journal of Obstetrics and Gynecology of India. Springer. 2012, February. 62(1):5-14
29.Kardakis S. Fertility-preserving surgery in patients with early stage cervical carcinoma. (2012). ISRN Oncology. Hindawi Publishing Corporation. 2012:817065
30.Nick AM, Frumovitz MM, Soliman PT, et al. Fertility sparing surgery for treatment of early-stage cervical cancer: open vs. robotic radical trachelectomy. (2012, February). Gynecologic Oncology. Academic Press. 2012, February. 124(2):276-80
31.Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical Reviews in Oncology/Hematology. Elsevier. 2011, March. 77(3):163-71
32.Miller DS, Blessing JA, Ramondetta LM, et al. GOG0076-GG: A limited access phase II trial of pemetrexed (LY231514) (NSC #698037) in combination with cisplatin (NSC #119875) in the treatment of advanced, persistent, or recurrent carcinoma of the cervix—A Gynecologic Oncology Group study. 2013. American Society of Clinical Oncology 2013
33. Xiong Y, Liang LZ, Cao LP, et al. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecologic Oncology. Academic Press. 2011, October. 123(1):99-104
34.Chen CC, Lin JC, Jan JS, et al. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecologic Oncology. Academic Press. 2011, July. 122(1):9-13
35.Folkert MR, Shih KK, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Gynecologic Oncology. Academic Press. 2013, February.128(2):288-93
36.Mountzios G, Soultati A, Pectasides D, et al. Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents. Obstetrics and Gynecology International. Hindawi Publishing. 2013:536765
37.Gil-Martin M, Olivera M, Pardo B, et al. Concurrent chemoradiation therapy in cervical cancer: Prognostic factors, toxicity, and long-term survival in a center of reference for gynecologic cancer. (2013). American Society of Clinical Oncology 2013
38.Soliman PT, Sun CC, Westin SN, et al. Longitudinal quality of life (QOL) and sexual functioning in women undergoing pelvic exenteration for gynecologic malignancies. (2013). American Society of Clinical Oncology 2013
39.Craighead P, Shea-Budgell MA, Nation J, et al. Hyperbaric oxygen therapy for late radiation tissue injury in gynecologic malignancies. Current Oncology. Toronto, ON: Multimed Inc. (2011, October).18(5):220-7
40. Cancer-cervix page. Mdguidelines: American Medical Association: 991-2014.
.png)
